Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer

Trial Details

NCT ID

NCT05653453

Phase

PHASE3

Sponsor

Jiangsu Healthy Life Innovation Medical Technology Co., Ltd

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

• Tumor treating fields combined with Gemcitabine hydrochloride and albumin binding paclitaxel
• Gemcitabine hydrochloride and albumin binding paclitaxel

Locations (sample)

• Harbin, Heilongjiang, China|45.75,126.65
• Jinan, Shandong, China|36.66833,116.99722
• Shanghai, Shanghai Municipality, China|31.22222,121.45806
• Shanghai, Shanghai Municipality, China|31.22222,121.45806
• Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

• Subjects aged between 18 and 75 (including 18 and 75) of both genders;
• Expected survival time ≥3 months;
• Pancreatic adenocarcinoma confirmed by histology/cytology;
• Locally advanced lesions meeting any of the following criteria without distant metastasis: ① Pancreatic head and neck tumors: a. The tumor invaded …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.